Xconomy | Seattle - Business + Technology in the Exponential Economy

Biotech, cancer, deals

Seattle Genetics Gets $12M From Agensys

Luke Timmerman 11/23/09

Seattle Genetics, the Bothell, WA-based developer of cancer drugs, said today it will get a $12 million upfront fee from Agensys, an affiliate of Japan-based Astellas Pharma, under a renegotiated partnership to develop targeted antibody treatments loaded with toxins to make them more potent. Seattle Genetics (NASDAQ: SGEN) struck its first partnership with Agensys in January 2007, but the new partnership allows for the two companies to collaborate on multiple new targets of cancer drugs.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.